This study revealed a 23% reduction in the risk of PCa associated with non-steroidal anti-inflammatory drugs (NSAIDs) and an even stronger association among patients treated with cyclooxygenase 2 (COX-2) inhibitors. Here, PTGS2 is linked to posterior cortical atrophy.